All In Biotech

Drug Trial Radar · NCT02739568

Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA

Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness

Last checked: Nov 19, 2026Latest source record: Jul 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 389 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

389

Actual

Start

Apr 2016

Primary completion

Apr 2020

Study completion Apr 2020

Sponsor

Lead sponsor
BioprojetAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The first objective of this study is to demonstrate the efficacy and safety of pitolisant given at 10, 20, or 40 mg per day versus placebo during 12 weeks of the Double Blind period, to treat the Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapy or treated by nCPAP but still complaining of EDS. The secondary objectives of the study include assessing the long-term tolerance as well as the maintenance of efficacy of pitolisant given at 10, 20 or 40 mg per day during 39 weeks of Open Label Extension period and further investigating the co-variates or co-medications that affect the pharmacokinetics of pitolisant in the target population.

Conditions

  • Excessive Daytime Sleepiness
  • Obstructive Sleep Apnea

Interventions

  • Pitolisant (BF2.649)Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Epworth sleepiness scale (ESS)Time frame: at weeks 12 and 52

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Specialised Hospital for Active Treatment of pneumo-phthisiatric diseases - Burgas" EOOD, Pneumology ward

    Burgas, Bulgaria

  • Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski" EOOD

    Kozloduy, Bulgaria

  • Multiprofile Hospital for Active Treatment "Sv. Paraskeva" OOD

    Pleven, Bulgaria

  • University Multiprofile Hospital for Active Treatment "Kaspela" EOOD Clinic of thoracic surgery

    Plovdiv, Bulgaria

  • University Multiprofile Hospital for Active Treatment "Aleksandrovska" EAD

    Sofia, Bulgaria

  • Hospital of Skopje

    Skopje, North Macedonia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.